29 completed, 14 terminated, 6 unknown, 6 withdrawn. 23 Phase 3, 16 Phase 2, 9 Phase 1, 7 Phase 4, 1 Not applicable.
Follow Uveitis, Intermediate: new trials by email Literature Review of Uveitis, Intermediate trials Research Report on Uveitis, Intermediate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adalimumab Dose Adjustment for Pediatric Uveitis Treatment Trial Adalimumab/Biosimilar - Juvenile Idiopathic Arthritis Associated Uveitis, Uveitis, Anterior | Phase 4 | Not yet recruiting | Nisha Acharya | 160 | 2026-09-01 | 2026-07-13 |
| A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis Brepocitinib PO QD, Placebo PO QD - Uveitis, Posterior, Uveitis, Intermediate | Phase 3 | Active not recruiting | Priovant Therapeutics, Inc. | 371 | 2024-09-11 | 2026-01-12 |
| POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU ESK-001 - Uveitis Posterior Non-Infectious, Uveitis, Intermediate | Phase 2 | Terminated | Alumis Inc | 36 | 2023-06-14 | 2024-08-28 |
| The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment Yutiq 0.18 MG Drug Implant, Sham Injection - Uveitis, Uveitis, Posterior | Phase 3 | Completed | Texas Retina Associates | 10 | 2022-10-05 | 2026-10-05 |
| Intravitreal Sirolimus as Therapeutic Approach to Uveitis Intravitreal injection 440mcg, Intravitreal injection of sirolimus 880mcg - Uveitis, Intermediate Uveitis | Phase 2 | Withdrawn | Stanford University | 2022-09-01 | 2023-10-26 | |
| Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis Izokibep, Placebo - Uveitis | Phase 2 | Terminated | ACELYRIN Inc. | 96 | 2022-08-23 | 2025-02-21 |
| Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study Ixekizumab Prefilled Syringe - Uveitis, Posterior, Uveitis, Anterior | Phase 4 | Unknown | Massachusetts Eye Research and Surgery Institution | 20 | 2022-06-01 | 2023-10-16 |
| Results of Suprachoroidal Steroids Injections in Two Chorioretinal Diseases Triamcinolone Acetonide - Central Serous Chorioretinopathy, Irvine-Gass Syndrome | Phase 2 / Phase 3 | Unknown | Benha University | 50 | 2022-04-14 | 2022-04-20 |
| Ozurdex Monotherapy Trial Ozurdex 0.7mg Ophthalmic Implant, Prednisone - Uveitis, Posterior, Uveitis, Intermediate | Phase 4 | Withdrawn | Ottawa Hospital Research Institute | 2021-11-30 | 2025-03-12 | |
| Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert Sham Injector, FAI Insert - Uveitis, Uveitis, Posterior | Phase 3 | Terminated | EyePoint Pharmaceuticals, Inc. | 12 | 2021-10-13 | 2024-12-19 |
| Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole Episcleral Celecoxib - Macula Edema, Radiation Retinopathy | Phase 1 | Unknown | Targeted Therapy Technologies, LLC | 3 | 2021-03-05 | 2023-11-24 |
| Adalimumab in JIA-associated Uveitis Stopping Trial Adalimumab, Placebo - Uveitis, JIA | Phase 4 | Completed | Nisha Acharya | 87 | 2020-03-15 | 2025-05-11 |
| Pilot Project: The Amplicon and Metatranscriptomic Study of Intra and Extra Intestinal Microbiome in Non-infectious Uveitis Disease Autoimmune Uveitis, Behçet Disease | Unknown | Fakultas Kedokteran Universitas Indonesia | 10 | 2019-11-01 | 2019-10-17 | |
| Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole Episcleral Dexamethasone - Macular Edema, Radiation Retinopathy | Phase 1 | Unknown | Targeted Therapy Technologies, LLC | 2 | 2019-09-01 | 2023-11-24 |
| Safety &Efficacy of CF101 to Subjects With Uveitis CF101, Placebo - Uveitis, Posterior, Uveitis, Intermediate | Phase 2 | Withdrawn | Can-Fite BioPharma | 2019-01-01 | 2018-02-01 | |
| Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer) Acthar Gel - Uveitis, Posterior, Uveitis, Intermediate | Phase 4 | Terminated | Mallinckrodt | 5 | 2018-10-05 | 2021-08-03 |
| MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301 4 mg CLS-TA Suprachoriodal Injection, Sham procedure - Uveitis, Uveitis, Posterior | Completed | Clearside Biomedical, Inc. | 33 | 2017-12-13 | 2021-06-02 | |
| ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study) ACTH gel - Uveitis | Phase 2 | Completed | Quan Dong Nguyen | 28 | 2017-11-10 | 2025-12-17 |
| Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis 4 mg CLS-TA Suprachoriodal Injection - Uveitis, Uveitis, Posterior | Phase 3 | Completed | Clearside Biomedical, Inc. | 38 | 2017-04-04 | 2021-06-23 |
| Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study) Ustekinumab - Uveitis | Phase 2 | Completed | National Eye Institute (NEI) | 8 | 2017-03-30 | 2021-03-26 |
Showing 20 of 57. Sign in to see all of them.
Uveitis (40) · Uveitis, Posterior (40) · Panuveitis (25) · Uveitis, Anterior (11) · Macular Edema (8) · Behcet Syndrome (4) · Inflammation (3) · Choroidal Effusions (2) · Epiretinal Membrane (2) · Ophthalmia, Sympathetic (2) · Pars Planitis (2) · Retinal Vein Occlusion (2) · Scleritis (2) · Birdshot Chorioretinopathy (1)
Uveal Diseases (57) · Eye Diseases (56) · Panuveitis (22) · Uveitis (17) · Retinal Diseases (10) · Vascular Diseases (9) · Cardiovascular Diseases (8) · Macular Degeneration (8) · Retinal Degeneration (8) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6) · Choroid Diseases (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Nervous System Diseases (5) · Skin Diseases, Vascular (5)
secukinumab (7) · Triamcinolone Acetonide (5) · Adalimumab (3) · Adrenocorticotropic Hormone (3) · salicylhydroxamic acid (3) · Fluocinolone Acetonide (2) · Methotrexate (2) · Prednisone (2) · Adrenal Cortex Hormones (1) · Biosimilar Pharmaceuticals (1) · Bulk Drugs (1) · CF101 (1) · Calcium Dobesilate (1) · Contraceptives, Oral (1) · Dexamethasone (1)
National Eye Institute (NEI) (8) · Novartis Pharmaceuticals (6) · Clearside Biomedical, Inc. (5) · XOMA (US) LLC (3) · EyePoint Pharmaceuticals, Inc. (2) · Johns Hopkins University (2) · Lux Biosciences, Inc. (2) · Nisha Acharya (2) · Targeted Therapy Technologies, LLC (2) · ACELYRIN Inc. (1) · AbbVie (1) · Allergan (1) · Alumis Inc (1) · Asociación para Evitar la Ceguera en México (1) · Benha University (1)
United States (44) · Germany (16) · United Kingdom (12) · Israel (11) · India (10) · Spain (10) · France (9) · Canada (8) · Austria (7) · Italy (7) · Australia (6) · Greece (6) · Switzerland (6) · Brazil (5) · Turkey (Türkiye) (5)
Thomas Ciulla, MD (4) · Hatice N Sen, M.D. (3) · Quan D Nguyen, MD, MSc (3) · Eddy Anglade, M.D. (2) · Nisha Acharya, MD MS (2) · Theodore Leng, MD (2) · Ahmed A Abdelshafy, MD (1) · Arnd Heiligenhaus, MD (1) · C. Stephen Foster, MD, FACS, FACR (1) · Christoph Deuter, Dr. (1) · Donald Betah (1) · Emily Y Chew, M.D. (1)
PMID 23290985, PMID 36787524, PMID 36399237, PMID 18639220, PMID 20926833, PMID 21220619, PMID 23411886, PMID 23761087, PMID 25638011, PMID 25918559, PMID 26582161, PMID 27980877, PMID 29370572, PMID 33042579, PMID 33157077, PMID 34322164, PMID 34741564, PMID 36055922, PMID 36912792, PMID 37172782, PMID 38027419, PMID 38925285, PMID 39863370
2009 (7), UG1EY029658 (1), UG1EY038172 (1)